Search PubMed⌕ Search

Biomedical subjects

K Derzsiová

Publications and source records attributed to K Derzsiová.

At least 19 recordsLinked to original sources
PubMed2005

The disease of Franz Kafka.

On June 3, 2004, 80 years have passed since the death of one of the greatest and the most important world writers of 20th century, the Prague German writer Franz Kafka. On November 5, 2004 we reminded that remarkable anniversary, which was also the 3rd anniversary of revelation of the monument of Franz Kafka in Tatranské Matliare, the High Tatras. Franz Kafka suffered from lung tuberculosis from 1917 until his death 1924. He was treated on lung tuberculosis in the sanatorium "Villa Tatra" from December 20, 1920 until August 27, 1921 in Tatranské Matliare, the High Tatras. Lung tuberculosis was a very dangerous disease in that time and the treatment by dietotherapy, climatotherapy and symptomatic therapy without antituberculotic drugs was less effective in many patients. In the paper the disease of Franz Kafka was described according to available literature.

Czech Republic↗
PubMed2004

[Continuous ambulatory peritoneal dialysis and respiratory pulmonary functions].

Acidobasic balance and respiratory pulmonary functions were examined in 15 patients with chronic renal insufficiency during continuous ambulatory peritoneal dialysis (CAPD) using a dialysis solution containing 1.5% or 2.5% of glucose. Patients did not suffer from any pulmonary disease nor ischemic heart disease. Biochemical indicators of acidobasic balance were in reference range or on its lower margin. Respiratory pulmonary functions were in tolerance except maximum expiratory flow volume at 50% and 25% of vital capacity (MEF50 and MEF25) and except diffusion lung capacity (DLCO) which were decreased. Decrease of maximum expiratory flow could be caused by a loss of elasticity of pulmonary parenchyma and by a beginning increased resistance in peripheral pulmonary ways. Decreased DLCO was identified in majority of patients and was caused by anaemia and a minimal interstitial pulmonary edema. Use of a single peritoneal dialysis with dialysis solutions of various glucose concentrations did not have any significant effect on acidobasic balance markers nor pulmonary respiratory functions.

Acid-Base Equilibrium↗
PubMed2004

105th birth anniversary of professor Frantisek Pór, M.D.

Professor Frantisek Pór, M.D., was one of the most remarkable physicians in Czechoslovakia. He graduated at the German Medical Faculty of Charles University in Prague, in 1926. He was a founder of the First Internal Clinic of the Medical Faculty of P J. Safárik University and of the Faculty Hospital in Kosice. Prof. F. Pór, M.D., was the Head of the First Internal Clinic from 1948 until 1971. During his active professional life he educated 11 associate professors and 3 full professors. He was also a founder of Eastern Slovakian Medical Meetings in Nový Smokovec, the High Tatras, in 1961. The "Memorial Meeting of Professor F. Pór, M.D." has been organized by the Medical Society in Kosice since 1994. The last one was held in the Faculty Hospital of L. Pasteur in Kosice, on April 28, 2003.

Czechoslovakia↗
PubMed2003

[History of nephrology and extracorporeal drug removal at the L. Pasteur Hospital in Kosice].

The authors describe the development of clinical nephrology from 1948 to 2002 at the Medical Faculty of the P. J. Safarík University and L. Pasteur Faculty Hospital from the aspect of therapeutic and preventive care, teaching and research activities. The dialysis centre which was established in 1966 at the Medical Clinic of the Faculty Hospital in Kosice continued in the activities as the Nephrological laboratory which was founded in 1954. This laboratory still operates under the conditions of the Nephrological Clinic. In 1964 at the Medical Clinic the first percutaneous renal biopsy was implemented. In 1966 the first peritoneal dialysis was implemented and the first haemodialysis in a patient with chronic renal failure, later gradually all so far known therapeutic methods were introduced which replace renal function and are used in acute and chronic renal failure and in acute intoxication. On March 18, 1977 in the authors' department the first haemoperfusion over active charcoal was made successfully in a patient intoxicated with parquat. It was the first haemoperfusion in the former Czechoslovak Republic. From 1991 at the Clinic a Sub-chair of nephrology and dialysis was established attached to the Institute for Postgraduate Training, later SPAM. Within the framework of the latter several nephrological courses were organized as well as courses in extracorporeal elimination treatment and in acute toxicology. The department acted also as a training place for future nephrologists before the specialization examination in nephrology. Since 1981 successfully several research grants concerned with the use of haemoperfusion over active charcoal and other sorbents in acute intoxications were completed as well as grants focused on metabolic vitamin disorders in chronic renal failure. On October 24 1997 in our department within the framework of the P. J. Safarík University Medical Faculty and L. Pasteur Faculty Hospital the Nephrological Clinic was established, the first one in the Slovak Republic. This stimulated further qualitative development of nephrology not only in Kosice but in the whole of Slovakia.

Hemoperfusion↗
PubMed2003

[Tenth memorial of professor Frantisek Pór, MD].

Professor Frantisek Pór, MD, was one of the most important physicians in Czechoslovakia. He graduated in German Medical Faculty of Charles University in Prague in 1926. He was a founder of the first Internal Clinic of Medical Faculty of P. J. Safárik University and of Faculty Hospital in Kosice. Professor F. Pór, MD, was the head of the 1st Internal Clinic from 1948 until 1971. During his active professional life he educated eleven assistant professors and three full professors. He was also a founder of Eastern Slovakian Medical Meetings in Nový Smokovec, High Tatras in 1961. Medical Society in Kosice organized "Memorial of Professor F. Pór, MD" from 1994 every year and the last was held in April 28, 2003 in Faculty Hospital of L. Pasteur in Kosice.

History, 20th Century↗
PubMed2002

Vitamin E as an antioxidant agent in CAPD patients.

Oxidative stress, increased lipid peroxidation and decreased activity of antioxidant systems may contribute to the accelerated development of atherosclerosis in chronic renal failure patients during renal replacement therapy. The aim of the study was to investigate the influence of vitamin E (400 mg/day) on some antioxidant defense parameters in CAPD patients. In fourteen CAPD patients, erythrocyte antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPX) and catalase (CAT), the concentration of plasma malondialdehyde (MDA), vitamin A, vitamin C and vitamin E were investigated. The study was divided into two periods. Each period lasted six weeks. In the first period patients received orally vitamin E 400 mg/day, in the second period they did not receive vitamin E or other antioxidant drugs. Each parameter was determined at the beginning of the study and at the end of each period. Six CAPD patients were treated by erythropoietin (EPO) and received orally pyridoxine 20 mg/day and the others without EPO treatment received pyridoxine 5 mg/day. Six-week treatment by vitamin E (400 mg/day) led to the significant increase of serum vitamin E (from 33.6+/-9.0 to 49.3+/-15.5 micromol/L) and to the significant decrease of MDA (from 2.62+/-0.5 to 2.36+/-0.4 micromol/L). The mean values of erythrocyte enzymes were in or under the lower margin of normal range and were not influenced by vitamin E in CAPD patients. The results of our study showed that orally administered vitamin E is a very important antioxidant agent for CAPD patients.

Administration, Oral↗
PubMed2002

[Diagnosis and therapy of ethylene glycol poisoning--analysis of 20 patients].

The paper presents a retrospective analysis of 20 patients with acute ethylene glycol intoxication who were treated from 1972 to 2001 in the Dialysis Centre of the IVth Medical Clinic and from 1997 at the L. Pasteur Nephrological Clinic of the Faculty Hospital and Safarík Medical Faculty in Kosice. The ethylene glycol intoxication was manifested by neurological symptoms, extreme metabolic acidosis, acute toxic hepatitis and acute renal failure. Laboratory examination revealed oxaluria in 17 patients and leukocytosis in all patients. Percutaneous renal biopsy was made for differential diagnostic or forensic reasons in the convalescent stage of acute renal failure in 6 patients. In the treatment of ethylene glycol intoxication the authors used ethyl alcohol as an antidote: in the first four patients administered by the i.v. route, in the remaining patients in dialyzation solution. Extreme metabolic acidosis improved in 15 patients after bicarbonate haemodialysis. Concomitant application of haemoperfusion over active charcoal during the first haemodialysis in four patients led to a potentiated effect on the uraemic syndrome. Conservative and extracorporeal elimination treatment of ethylene glycol intoxication succeeded in 16 patients (80%). According to the authors' experience early and fractionated application of bicarbonate haemodialysis with 100 mg% concentration of ethylalcohol in the dialysis solution is the method of choice in the treatment of ethylene glycol intoxication.

Acute Disease↗
PubMed2001

A modified dialyzer with vitamin E and antioxidant defense parameters.

BACKGROUND: Oxidative stress, increased lipid peroxidation, and decreased activity of antioxidant systems may contribute to the accelerated development of atherosclerosis in patients receiving hemodialysis therapy for chronic renal failure. We investigated the influence of vitamin E on antioxidant defense parameters in hemodialysis patients who were using a modified dialyzer. METHODS: In eight hemodialyzed patients, erythrocyte antioxidant enzymes, superoxide dismutase (SOD) and glutathione peroxidase (GPX), plasma total antioxidant capacity (TAC), the concentration of plasma malondialdehyde (MDA), and vitamins A, E, and C were investigated. Each parameter was measured before and after hemodialysis. The study was divided into three periods. Each period lasted three weeks, and during this time, 10 hemodialyses were performed. The first and second periods were carried out using the conventional dialyzer, Terumo CL-S15, but during the second period, patients received vitamin E 400 mg perorally after each hemodialysis. The third period was carried out using a modified dialyzer with vitamin E, Terumo CL-E15. All hemodialyzed patients were treated by erythropoietin and received vitamin C 50 mg/day and pyridoxine 20 mg/day during the entire study. RESULTS: The peroral administration of vitamin E led to a significant increase of serum vitamin E (22%), and no influence on other antioxidant defense parameters was found. The modified dialyzer with vitamin E led to a significant increase of serum vitamin E (33%) and TAC and to the significant decrease of plasma MDA. CONCLUSION: The results of our study suggest that the modified dialyzer with vitamin E provided more effective antioxidant defense than peroral administration of vitamin E in our hemodialysis patients.

Administration, Oral↗
PubMed2001

Renal replacement therapy and secondary hyperoxalemia in chronic renal failure.

Oxalic acid is one of the well-known uremic toxins that participates in the pathogenesis of uremic syndrome. Secondary hyperoxalemia is a common feature in patients with chronic renal failure, but oxalate removal is not adequately accomplished by renal replacement therapy. In our series of patients, the plasma level of oxalic acid was significantly elevated, while the plasma vitamin C was in the normal range or in the upper margin of the normal range. The peritoneal clearance of oxalic acid was significantly lower in comparison to the peritoneal clearance of urea. Peritoneal clearance and peritoneal transfer of oxalic acid and other examined parameters increased using dialysis solution containing 2.5% glucose in comparison to dialysis solution containing 1.5% glucose. The significant hyperoxalemia of our patients persisted despite the relatively high peritoneal transfer of oxalic acid during continuous ambulatory peritoneal dialysis. The clearance of oxalic acid related to the clearance of urea was 58.1% during hemodialysis, 74.2% during postdilution hemofiltration, and 69.0% during postdilution hemodiafiltration. The sieving coefficient of oxalic acid during postdilution hemofiltration was 74.0% of urea sieving coefficient. The most significant decrease of plasma oxalic acid was observed during postdilution hemodiafiltation (63.3%). These results suggest that currently, renal replacement therapy is not effective enough for a permanent reduction of plasma oxalic acid.

Adult↗
PubMed2001

[Oral administration of iron with vitamin C in haemodialyzed patients].

One tablet of Sorbifer Durules contains 100 mg Fe2+ and 60 mg vitamin C. The authors examined in a short-term study 24 haemodialyzed patients with chronic renal failure of different etiology. The investigation was divided into three parts. During the first 4 weeks the patients did not receive Fe2+ nor vitamin C. During the subsequent four weeks the patients had Sorbifer Durules, one tablet/24 hours. This period was followed by another four weeks when the patients went again without Fe2+ and vitamin C treatment. At regular intervals, i.e. on days 0, 28, 56 and 84 the authors assessed the packed cell volume, blood haemoglobin and serum iron level, the total iron binding capacity, transferrin saturation, ferritin, and vitamin C in serum as well as the plasma oxalic acid level. Four weeks treatment using Sorbifer Durules led to a significant rise of the packed cell volume and haemoglobin in blood, iron and vitamin C in serum. This treatment did not affect the oxalic acid plasma level. Oral treatment with Sorbifer Durules, one tablet/24 hours, was adequate for maintaining the serum iron concentration in haemodialyzed patients during treatment with recombinant human erythropoietin. This treatment prevented at the same time the development of vitamin C deficiency in serum and a further rise of plasma oxalic acid in these patients.

Administration, Oral↗
PubMed1999

Hemoperfusion study with carbamazepine in vitro.

Sorption efficacy of active charcoal, Amberlite XAD-2 and Amberlite XAD-4 in hemoperfusion with carbamazepine was investigated in vitro. Authors carried out 15 hemoperfusions with carbamazepine in a closed system using the above mentioned sorbents; The perfusion solution used was 3,000 ml of 0.9% NaCl. The carbamazepine concentration in the solution was 52.5+/-3.0 mg/L. In addition, two in vitro hemoperfusions with carbamazepine using Amberlite XAD-2 sorbent and 1.500 ml of human plasma as a perfusion solution, were also performed. The concentration of carbamazepine in plasma was 50.4+/-1.2 mg/L. Individual hemoperfusions lasted 5 hours. Zero values of carbamazepine were achieved after 120 min of Amberlite XAD-2 or Amberlite XAD-4 hemoperfusion in 0.9% NaCl and after 240 min of hemoperfusion in human plasma. The results gathered suggest that the most effective in vitro hemoperfusion with carbamazepine was obtained with Amberlite XAD-2 or Amberlite XAD-4 and the least effective was with active charcoal. The authors recommend the use of hemoperfusion with Amberlite XAD-2 or Amberlite XAD-4 for acute intoxications with carbamazepine in humans. In addition, authors successfully performed 5-hour hemoperfusion using Amberlite XAD-4 in vivo, in an 18-year-old girl, who suffered from acute carbamazepine intoxication after a suicidal attempt. This treatment led to the rapid survival.

Adolescent↗
PubMed1998

Peritoneal clearance and peritoneal transfer of oxalic acid, vitamin C, and vitamin B6 during continuous ambulatory peritoneal dialysis.

The peritoneal clearance and peritoneal transfer of oxalic acid, vitamin C, and vitamin B6 in 32 patients during continuous ambulatory peritoneal dialysis (CAPD) using peritoneal dialysis solutions containing 1.5% or 2.5% glucose were examined. The plasma level of oxalic acid was significantly elevated in all patients, plasma vitamin C was in the normal range or in the upper margin of the normal range, and plasma vitamin B6 was in the normal range. The peritoneal clearance of oxalic acid was significantly lower, and the peritoneal clearance of vitamin B6 was the lowest in comparison to the peritoneal clearance of urea. With the exception of vitamin B6, the peritoneal clearance and peritoneal transfer of the examined parameters increased using the dialysis solution containing 2.5% glucose. We found direct relationships between the plasma levels of oxalic acid and creatinine as well as plasma vitamin C and between the peritoneal transfer of oxalic acid and the peritoneal transfer of vitamin C as well as vitamin B6. The significant hyperoxalemia of our patients was found to persist despite the relatively high peritoneal transfer of oxalic acid during CAPD. These results suggest that CAPD is not a method effective enough for permanent reduction of the plasma levels of oxalic acid.

Adult↗
PubMed1998

[The effect of furosemide on urinary excretion of oxalic acid, vitamin C and vitamin B6 in chronic kidney failure].

The authors describe the effect of a single i.v. dose of 20 mg furosemide on the excretion of oxalic acid, vitamin C and vitamin B6 in a control group and in patients with chronic renal failure without dialyzation treatment. An increased urinary excretion of oxalic acid, vitamin C and vitamin B6 was found during the first three hours after furosemide administration in both groups. The effect of furosemide persisted for six hours in patients with chronic renal failure without dialyzation treatment. The authors described a new hitherto unknown positive side-effect of furosemide, i.e. enhanced urinary oxalic acid excretion in the control group and in patients with chronic renal failure without dialyzation treatment and a negative side-effect of furosemide, i.e. increased urinary vitamin B6 excretion in both examined groups. With regard to the assembled results the authors recommend in addition to monitoring of vitamin C also monitoring of vitamin B6 in plasma during long-term administration of large doses of furosemide to patients with chronic renal failure as deficiency of these vitamins could develop.

Adult↗
PubMed1997

Hemoperfusion with alpha-amanitin: an in vitro study.

The authors carried out sixteen hemoperfusions with alpha-amanitin in vitro in a closed system using active charcoal, Amberlite XAD-2 and Amberlite XAD-4 in hemoperfusion capsules. As a perfusion solution 4 liters of 0.9% NaCl solution was used. The alpha-amanitin concentration in the solution was 8.3 +/- 0.36 mg/L. Individual hemoperfusion lasted 5 hours. Two hundred and forty minutes of Amberlite XAD-2 hemoperfusion led to the zero values of alpha-amanitin concentration in 0.9% NaCl solution. When using active charcoal the adsorption capacity of the hemoperfusion capsule was already exhausted at 120 min. The results gathered suggest that the most effective alpha-amanitin hemoperfusion in vitro was obtained with Amberlite XAD-2 and the least effective with active charcoal. The authors recommend the use of hemoperfusion with Amberlite XAD-2 for acute intoxication with Amanita phalloides in humans up to 24-36 hours after poisoning.

Adsorption↗
PubMed1997

Metabolism of vitamin B6 and its requirement in chronic renal failure.

Vitamin B6 is very important for the normal function of multiple organ systems. In the majority of patients with chronic renal failure and in patients during various forms of renal replacement therapy can develop vitamin B6 deficiency from many causes. Intravenous administration of 20 mg furosemide led to the increase of urinary excretion and fraction excretion (FE) of vitamin B6 in patients with chronic renal failure. This is a new side effect of furosemide. The daily oral dose of pyridoxine 6 mg was optimal for the patients without erythropoietin (EPO) treatment during the period of 12 months of CAPD. Erythrocyte vitamin B6 was determined by an indirect method, that is, by measuring the effect of pyridoxal-5-phosphate (PLP). In the other group of CAPD patients plasma vitamin B6 was in the reference range, and the mean value of peritoneal clearance of vitamin B6 was very low: 8.8% of urea clearance. In addition, an indirect relationship between the effect of PLP and plasma vitamin B6 was found. Indirect evidence has shown that erythrocyte vitamin B6 is consumed by the hemoglobin synthesis much more during EPO treatment in hemodialysis patients. No influence of pyridoxine 5 to 6 mg/day on decreased parameters of cellular immunity was found. For prevention of vitamin B6 deficiency in hemodialysis and CAPD patients we recommend the following doses of pyridoxine: for patients without EPO treatment 5 mg/day, and with EPO treatment 20 mg/day. A favorable effect of pyridoxine 50 mg/day has also been found on several parameters of cellular immunity in hemodialysis patients.

Adult↗
PubMed1996

[Urinary oxalic acid excretion in chronic kidney failure and after kidney transplantation].

Urinary oxalic acid excretion was examined in 61 patients with chronic nephropathies and in 21 patients after renal transplantation with a varying mean glomerular filtration. In both groups of patients a correlation was found between the plasma oxalic acid and serum creatinine and by a hyperbolic correlation between plasma oxalic acid and creatinine clearance. Moreover the authors found a direct correlation between oxalic acid and FEoxalic acid and FE(Na)+, FEH20 and FE1-ascorbic acid in both patient groups. Various chronic nephropathies and treatment in both groups did not affect the revealed correlations. In 13 healthy subjects during the period of maximum water diuresis urinary Na+ excretion did not increase but there was a significant increase of the l-ascorbic acid and oxalic acid excretion. In a group of 8 patients in the polyuric stage of chronic renal failure without dialysis treatment under conditions of increased dietary NaCl intake (15 g/24 h) a significant increase of the urinary Na+ excretion was recorded while the l-ascorbic acid and oxalic acid excretion was unaltered. From the assembled values of the examined biochemical indicators ensues that urinary oxalic acid excretion, similarly as ascorbic acid excretion, depended on water excretion.

Adult↗
PubMed1995

[Hemoperfusion with Amberlite XAD-4 in acute theophylline poisoning].

Haemoperfusion through Amberlite XAD-4 was used in a female patient who took with suicidal intention 29 tablets of Syntophylline. During 5 hours of haemoperfusion the theophylline plasma concentration declined significantly to the lower limit of the therapeutic range. Early application of haemoperfusion, using Amberlite XAD-4, led to rapid regression of symptoms of acute intoxication and recovery of the patient.

Acute Disease↗